Lbp Am Sa Sells 7,530 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

LBP AM SA decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 205,305 shares of the biopharmaceutical company's stock after selling 7,530 shares during the period. LBP AM SA's holdings in Gilead Sciences were worth $23,004,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Cornerstone Planning Group LLC lifted its position in Gilead Sciences by 143.6% during the first quarter. Cornerstone Planning Group LLC now owns 743 shares of the biopharmaceutical company's stock valued at $79,000 after purchasing an additional 438 shares during the period. Linden Thomas Advisory Services LLC increased its holdings in Gilead Sciences by 3.1% during the first quarter. Linden Thomas Advisory Services LLC now owns 45,897 shares of the biopharmaceutical company's stock valued at $5,143,000 after buying an additional 1,366 shares during the last quarter. Greenleaf Trust increased its holdings in Gilead Sciences by 8.6% during the first quarter. Greenleaf Trust now owns 28,827 shares of the biopharmaceutical company's stock valued at $3,230,000 after buying an additional 2,279 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in Gilead Sciences by 0.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 2,057,579 shares of the biopharmaceutical company's stock valued at $229,294,000 after buying an additional 17,085 shares during the last quarter. Finally, Personal CFO Solutions LLC increased its holdings in Gilead Sciences by 82.8% during the first quarter. Personal CFO Solutions LLC now owns 4,099 shares of the biopharmaceutical company's stock valued at $459,000 after buying an additional 1,857 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Price Performance

GILD stock traded up $1.30 during trading on Thursday, hitting $114.54. 6,096,837 shares of the company's stock traded hands, compared to its average volume of 7,706,475. Gilead Sciences, Inc. has a 52 week low of $68.14 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The business has a fifty day simple moving average of $107.62 and a 200 day simple moving average of $104.50. The stock has a market capitalization of $142.48 billion, a price-to-earnings ratio of 24.11, a P/E/G ratio of 0.73 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the business earned ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares in the company, valued at approximately $13,238,908.56. This trade represents a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the sale, the chief financial officer owned 165,110 shares of the company's stock, valued at $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.